Hepatitis C recurrence: Influence of serum cholesterol levels and liver steatosis on antiviral therapy

Hepatology

Volumn 53, Issue 4, 2011, Pages 1409-1410

  Gianni, Testino ^a   Paolo, Borro ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL THERAPY; BODY MASS; CHOLESTEROL BLOOD LEVEL; FATTY LIVER; HEPATITIS C; HUMAN; LETTER; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; BODY MASS INDEX; CHOLESTEROL; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; TRIGLYCERIDES; VIRAL LOAD;

EID: 79953743331     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24034     Document Type: Letter

References (6)

1. Harrison SA, Rossaro L, Hu RQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. HEPATOLOGY 2010; 52: 864-874.
2. Testino G, Sumberaz A, Ravetti GL, Gentile R, Ansaldi F, Icardi GC. Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis. Dig Liver Dis 2006; 38: 860-861.
3. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation with etiology and immunosuppression. Liver Transpl 2008; 14: 1648-1654.
4. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-535.
5. Tarantino G, Conca P, Sorrentino P, Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 2006; 21: 1266-1268.
6. Jan Wu Y, Shu Chen L, Gui Qiang W. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 2006; 26: 166-172.